Matt Brokaw Is Appointed President and CEO of Aerin Medical

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

Matt Brokaw has been appointed President and Chief Executive Officer of Aerin Medical. He joins an experienced management team with a deep commitment to the ENT specialty.  Brokaw has a long record of commercial leadership, building successful ENT businesses at companies including Tusker Medical, Spirox, Entellus Medical, Stryker, Acclarent, Johnson & Johnson, and Smith+Nephew.

“Aerin is primed for its next phase of growth, propelled by non-invasive treatments embraced by patients, and in-office procedure options that are increasingly important to the ENT specialty,” said Brokaw. “I’m tremendously excited to join the team at this critical period, and I look forward to working in close partnership with the otolaryngology community and this experienced group of healthcare investors.”

Karen Long, Managing Director at KCK and Chairman of Aerin’s Board of Directors said, “We’re thrilled to add Matt’s leadership and operating experience to Aerin along with the business-scaling expertise and long-term capital partnership of Questa and OrbiMed.  With these partners and Matt at the helm, we have all the pieces in place to continue building a strong, sustainable growth company.”

In addition, Aerin Medical, announced the closing of a $48 million equity financing.  New investor Questa Capital led the round with participation by OrbiMed and existing investor KCK Group.  Proceeds from the financing will be used to accelerate commercial growth, support new clinical studies, and develop new products to better serve otolaryngologists (ear, nose and throat physicians or “ENTs”) and their patients. As part of the investment, Questa Capital Founder and Managing Partner Ryan Drant will join the Aerin board of directors.

Aerin provides ENTs with tissue-sparing solutions for the treatment of nasal conditions to improve patient quality of life.  ENT physicians use the company’s VivAer® and RhinAer® platform technologies to treat patients suffering from nasal airway obstruction and chronic rhinitis, respectively—prevalent and debilitating conditions that affect tens of millions of people in the U.S. annually.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.